Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of the Cleavage of the Egg in Relation to the Stimulation Treatment

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Ferring Pharmaceuticals Identifier:
First received: August 21, 2012
Last updated: May 3, 2016
Last verified: May 2016
This post-marketing, single-center prospective study will be conducted in an open-label, non-interventional setting, for women seeking fertility treatment and will describe cleavage dynamics in relation to the age of the oocyte and gonadotrophin treatment.

Female Infertility

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Kinetics in Time-lapse Culture of Human Preembryos

Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Time to 2. polar body extrusion in transferred embryos (only Intracellular Sperm Injection) [ Time Frame: Week 1 after oocyte retrieval ] [ Designated as safety issue: No ]
  • Time for disappearance of pronuclei in transferred embryos [ Time Frame: Week 1 after oocyte retrieval ] [ Designated as safety issue: No ]
  • Time for first cleavage in transferred embryos [ Time Frame: Week 1 after oocyte retrieval ] [ Designated as safety issue: No ]
  • Time for cleavage to 3-cell embryo and 4-cell embryo in transferred embryos [ Time Frame: Week 1 after oocyte retrieval ] [ Designated as safety issue: No ]
  • Scoring of blastomere even-size, fragmentation and multinucleation at 4-cell stage [ Time Frame: Week 1 after oocyte retrieval ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total dose of gonadotrophin used [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Gonadotrophin dose per oocyte retrieved [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Number of oocytes retrieved [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Number of fertilized and cleaved oocytes [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Number of preembryos with top quality [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Implantation rate [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Ongoing pregnancy rate week 7 [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Live birth rate [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Enrollment: 272
Study Start Date: January 2013
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Group 1
Women treated with Menopur
Group 2
Women treated with Menopur and Bravelle


Ages Eligible for Study:   38 Years to 45 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women suffering from infertility

Inclusion Criteria:

  1. IVF/ICSI treatment
  2. Regular cycles of 25-35 days
  3. Follicle stimulation with Bravelle and/or Menopur
  4. Women aged 38-35 years
  5. Long agonist or short antagonist treatment
  6. Willing and able to understand a Danish, English or German patient information form
  7. Willing and able to provide written Informed Consent

Exclusion Criteria:

  1. BMI more than 35
  2. Presence of hydrosalpinx on ultrasound
  3. FSH more than 13 or antral follicle count (AFC) less than 4 at fertility investigation
  4. Known allergic reactions to the planned medications
  5. Use of testicular sperm
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01674894

Danish Fertility Clinic
Frederiksberg, Copenhagen, Denmark
Sponsors and Collaborators
Ferring Pharmaceuticals
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals Identifier: NCT01674894     History of Changes
Other Study ID Numbers: 000063 
Study First Received: August 21, 2012
Last Updated: May 3, 2016
Health Authority: Denmark: Danish Medicines Agency
Denmark: Danish Dataprotection Agency

Additional relevant MeSH terms:
Infertility, Female
Genital Diseases, Male
Genital Diseases, Female processed this record on January 14, 2017